NCT06773936 - Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 15, 2025

Primary Completion Date

May 31, 2029

Study Completion Date

July 31, 2033

Conditions

Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaCD19+ Acute Leukemia

Interventions

DRUG

Induction Phase

Asciminib, Dasatinib, Prednisone, and Methotrexate

DRUG

Re-Induction Phase

Blinatumomab, Dasatinib, Methotrexate, and Dexamethasone

DRUG

Post-Remission

Blinatumomab, Dasatinib, Methotrexate and Dexamethasone

DRUG

Maintenance

Asciminib, Dasatinib, Prednisone, and Methotrexate